Ascendis Pharma A/S (NASDAQ:ASND) Reaches New 52-Week High – Time to Buy?

Ascendis Pharma A/S (NASDAQ:ASND) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $168.74 and last traded at $167.04, with a volume of 130347 shares trading hands. The stock had previously closed at $152.98.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ASND shares. Cantor Fitzgerald upped their target price on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price on the stock. Finally, Morgan Stanley set a $180.00 price objective on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Stock Up 7.2 %

The business’s 50 day simple moving average is $138.31 and its two-hundred day simple moving average is $134.68. The stock has a market capitalization of $9.95 billion, a P/E ratio of -23.10 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.64. Analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtus ETF Advisers LLC increased its holdings in Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 100 shares during the last quarter. Legato Capital Management LLC lifted its holdings in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 197 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S during the 4th quarter valued at about $28,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at about $30,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.